Should ketamine be used for the clinical treatment of depression?

Research output: Contribution to journalReview ArticleOtherpeer-review

2 Citations (Scopus)

Abstract

Objective: There has been widespread interest from the public and media in the potential of ketamine as a novel treatment for depression. This paper reviews whether current evidence supports the use of ketamine for the clinical treatment of depression. Conclusions: Clinical trials have investigated the use of intravenous ketamine for the treatment of depressive symptoms over the past 15 years. However, there remain many unanswered questions regarding its effectiveness, safety, and the route, dose and regimen for repeated administration. Experts have also raised concerns regarding ketamine's adverse effects, abuse potential and the risk of addiction. At this stage, the use of ketamine in the treatment of depression remains in the realm of research settings.

Original languageEnglish
Pages (from-to)381-384
Number of pages4
JournalAustralasian Psychiatry
Volume24
Issue number4
DOIs
Publication statusPublished - 2016

Keywords

  • Depression
  • Ketamine
  • Pharmacotherapy

Cite this

@article{4ec6182e69ae4f1b9d97b8865a8858db,
title = "Should ketamine be used for the clinical treatment of depression?",
abstract = "Objective: There has been widespread interest from the public and media in the potential of ketamine as a novel treatment for depression. This paper reviews whether current evidence supports the use of ketamine for the clinical treatment of depression. Conclusions: Clinical trials have investigated the use of intravenous ketamine for the treatment of depressive symptoms over the past 15 years. However, there remain many unanswered questions regarding its effectiveness, safety, and the route, dose and regimen for repeated administration. Experts have also raised concerns regarding ketamine's adverse effects, abuse potential and the risk of addiction. At this stage, the use of ketamine in the treatment of depression remains in the realm of research settings.",
keywords = "Depression, Ketamine, Pharmacotherapy",
author = "Shalini Arunogiri and Keks, {Nicholas A.} and Judy Hope",
year = "2016",
doi = "10.1177/1039856216629839",
language = "English",
volume = "24",
pages = "381--384",
journal = "Australasian Psychiatry",
issn = "1039-8562",
publisher = "SAGE Publications Ltd",
number = "4",

}

Should ketamine be used for the clinical treatment of depression? / Arunogiri, Shalini; Keks, Nicholas A.; Hope, Judy.

In: Australasian Psychiatry, Vol. 24, No. 4, 2016, p. 381-384.

Research output: Contribution to journalReview ArticleOtherpeer-review

TY - JOUR

T1 - Should ketamine be used for the clinical treatment of depression?

AU - Arunogiri, Shalini

AU - Keks, Nicholas A.

AU - Hope, Judy

PY - 2016

Y1 - 2016

N2 - Objective: There has been widespread interest from the public and media in the potential of ketamine as a novel treatment for depression. This paper reviews whether current evidence supports the use of ketamine for the clinical treatment of depression. Conclusions: Clinical trials have investigated the use of intravenous ketamine for the treatment of depressive symptoms over the past 15 years. However, there remain many unanswered questions regarding its effectiveness, safety, and the route, dose and regimen for repeated administration. Experts have also raised concerns regarding ketamine's adverse effects, abuse potential and the risk of addiction. At this stage, the use of ketamine in the treatment of depression remains in the realm of research settings.

AB - Objective: There has been widespread interest from the public and media in the potential of ketamine as a novel treatment for depression. This paper reviews whether current evidence supports the use of ketamine for the clinical treatment of depression. Conclusions: Clinical trials have investigated the use of intravenous ketamine for the treatment of depressive symptoms over the past 15 years. However, there remain many unanswered questions regarding its effectiveness, safety, and the route, dose and regimen for repeated administration. Experts have also raised concerns regarding ketamine's adverse effects, abuse potential and the risk of addiction. At this stage, the use of ketamine in the treatment of depression remains in the realm of research settings.

KW - Depression

KW - Ketamine

KW - Pharmacotherapy

UR - http://www.scopus.com/inward/record.url?scp=84986593108&partnerID=8YFLogxK

U2 - 10.1177/1039856216629839

DO - 10.1177/1039856216629839

M3 - Review Article

VL - 24

SP - 381

EP - 384

JO - Australasian Psychiatry

JF - Australasian Psychiatry

SN - 1039-8562

IS - 4

ER -